|
Market Closed -
Nasdaq
00:00:00 10/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 151.17 USD | +2.77% |
|
+4.44% | +23.16% |
| 10-08 | RBC Lifts Price Target on Gilead Sciences to $126 From $123, Keeps Sector Perform Rating | MT |
| 10-07 | Pharmaceutical Group Sues US Government Over Medicare Drug Pricing Rule | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 187B | - | ||||
| 1,051B | |||||
| 630B | - | ||||
| 489B | |||||
| 359B | |||||
| 344B |
- Stock Market
- Stocks
- GILD Stock
- Charts Gilead Sciences, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
